IBEX 35
9.041,90 +208,80 (+2,36%) Euro Stoxx 50
4.190,98 +71,56 (+1,74%) Dólar/Euro
1,0747 +0,0021 (+0,19%) Petróleo Brent
74,47 +0,68 (+0,92%) Oro
1.973,00 -9,80 (-0,49%) Bitcoin EUR
26.114,74 -170,25 (-0,65%)
AbbVie Inc. (ABBV)
Antes de la apertura:
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com
Sector(es): Healthcare
Sector: Drug Manufacturers—General
Empleados a tiempo completo: 50.000
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 7,42M | 19,91M | 1954 |
| Mr. Robert A. Michael | Vice Chairman & Pres | 3,82M | N/A | 1970 |
| Ms. Laura J. Schumacher | Vice Chairman of External Affairs & Chief Legal Officer | 4,18M | 13,28M | 1963 |
| Mr. Jeffrey Ryan Stewart | Exec. VP & Chief Commercial Officer | 3,25M | N/A | 1969 |
| Mr. Scott T. Reents | Exec. VP & CFO | N/A | N/A | 1967 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Exec. VP of Operations | N/A | N/A | 1963 |
| Dr. Thomas Hudson M.D. | Sr. VP of R&D and Chief Scientific Officer | N/A | N/A | 1962 |
| Ms. Elizabeth Shea | VP of Investor Relations | N/A | N/A | N/A |
| Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
| Ms. Carrie C. Strom | Sr. VP of AbbVie & Pres of Global Allergan Aesthetics | N/A | N/A | 1978 |
Descripción
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Gobierno corporativo
El ISS Governance QualityScore de AbbVie Inc., a día 1 de marzo de 2023, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 4; Derechos de los accionistas: 9; Compensación: 6.
